ESSA Pharma Inc. (EPIX) Dividend History

ESSA Pharma Inc. (EPIX) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for prostate cancer. The company specializes in the research and development of novel drugs targeting androgen receptor signaling pathways to treat advanced prostate cancer, including castration-resistant prostate cancer. Founded with a focus on addressing unmet medical needs, ESSA Pharma aims to advance therapies that can overcome resistance to existing treatments.

Suite 720, Vancouver, A1, V5Z 1K5
Phone: (778) 331-0962
Website: https://www.essapharma.com

Dividend History

ESSA Pharma Inc. currently does not pay dividends

Company News

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma

ESSA Pharma announced the termination of its Phase 2 trial for a prostate cancer treatment, citing lack of efficacy and futility. This led to a significant drop in the company's stock price.

GlobeNewswire Inc.
EPIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against ESSA Pharma Inc. (EPIX) alleging the company made materially false and misleading statements about the efficacy of its drug masofaniten in combination with enzalutamide for treating prostate cancer.

GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma

ESSA Pharma announced the termination of its Phase 2 trial for a prostate cancer treatment, citing lack of efficacy and futility. The company's stock price fell significantly on this news.

GlobeNewswire Inc.
EPIX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EPIX

ESSA Pharma Inc. is facing a securities class action lawsuit due to alleged failure to disclose information about the efficacy of its drug masofaniten in combination with enzalutamide for treating prostate cancer. The lawsuit claims that the company overstated the drug's clinical, regulatory, and commercial prospects, leading to investor losses.

GlobeNewswire Inc.
ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. March 25, 2025 Deadline to file Lead Plaintiff Motion

ESSA Pharma Inc. investors are advised to contact the Portnoy Law Firm to recover losses, as the company allegedly made false and misleading statements about the efficacy of its drug combination treatment for prostate cancer.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 18:04:57 UTC